Get ready for Asthma and Allergy Awareness month 2024
Be prepared for this awareness month, when attention is focused on asthma and allergies. It’s a great opportunity to share your expertise!
Nominate a FIT for 2024 Annals Award
FITs who publish the best original research or review in Annals will receive a cash award of up to $2,500. Multiple winners are possible.
AllergyWatch covers important ABAI CAP articles
Did you complete the most recent ABAI CAP cycle? Were you able to read all of the key articles in the program?
CPT code 95165 – What’s a dose for Medicare billing?
Medicare defines a dose, for billing purposes only, as 1cc of extract and does not cover dilutions. Medicare reimbursement is based on this definition.
2023 MIPS Emergency Exception Applications reopened due to Change Healthcare cyberattack
CMS will only approve applications citing this cyberattack as the basis for requesting reweighting under the MIPS EUC Exception.
Coding Conundrum – E/M plus Testing
Recently we received a query from a member about coding an oral challenge and an office visit on the same day.
ACAAI practice manager membership
Is your practice manager/administrator a member of the College? If not, you’re missing an opportunity to elevate your practice – for free!
Change Healthcare Cyberattack – continuing coverage
Here is the latest update from UnitedHealth Group. We encourage you to bookmark and check the UHG site regularly for updates.
March 2024 Annals highlights
This month’s articles and reviews provide guidance for these changes in our treatment pathways.
AllergyTalk podcast features OUtMATCH study
The FDA announced its approval of omalizumab as the first biologic medication to treat patients with food allergy.
… results.
